---
content_type: page
description: 'This section provides the list of required and recommended readings
  for each session of the course. '
draft: false
learning_resource_types:
- Readings
ocw_type: CourseSection
title: Readings
uid: 2947c805-f872-6255-a8f2-ca8b8a286944
---
{{< tableopen >}}{{< theadopen >}}{{< tropen >}}{{< thopen >}}
SES #
{{< thclose >}}{{< thopen >}}
TOPICS
{{< thclose >}}{{< thopen >}}
READINGS
{{< thclose >}}{{< trclose >}}{{< theadclose >}}{{< tbodyopen >}}{{< tropen >}}{{< tdopen >}}
1
{{< tdclose >}}{{< tdopen >}}
Introduction From Discovery to Market: An Integrated View
{{< tdclose >}}{{< tdopen >}}

### Required

Jack, Andrew. "[Pharmaceuticals: Back to the Lab](http://www.ft.com/intl/cms/s/0/e5679dae-e565-11e2-ad1a-00144feabdc0.html#axzz3FNYFnrPK)," *Financial Times*, August 10, 2013.

Munos, B. "[Lessons from 60 Years of Pharmaceutical Innovation](http://dx.doi.org/10.1038/nrd2961)." *Nature Reviews Drug Discovery* 8 (2009): 959–68.

U.S. Food and Drug Administration. ["FY 2011 Innovative Drug Approvals." (PDF - 5.0MB)](http://www.biopreneur.org/images/FY%202011%20Innovative%20Drug%20Approvals.pdf) U.S. Department of Health and Human Services, U.S. Food and Drug Administration.

{{< tdclose >}}{{< trclose >}}{{< tropen >}}{{< tdopen >}}
2
{{< tdclose >}}{{< tdopen >}}
Brief Economic History of the Pharmaceutical Industry
{{< tdclose >}}{{< tdopen >}}

### Required

Rang, H. P., ed. Chapters 1–3 in *Drug Discovery and Development: Technology in Transition*. Churchill Livingstone, 2006, pp. 3–40. ISBN: 9780443064203.

Saftlas, Herman. "Healthcare: Pharmaceuticals." *Standard & Poor's Industry Surveys*. June 4, 2009. *S&P Net Advantage*.

U.S. Food and Drug Administration. ["FY 2011 Innovative Drug Approvals." (PDF - 5.0MB)](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM278358.pdf) U.S. Department of Health and Human Services, U.S. Food and Drug Administration.

{{< tdclose >}}{{< trclose >}}{{< tropen >}}{{< tdopen >}}
3
{{< tdclose >}}{{< tdopen >}}
The Pharmaceutical Industry and the Drug Development Process; Basic Science
{{< tdclose >}}{{< tdopen >}}
No Readings
{{< tdclose >}}{{< trclose >}}{{< tropen >}}{{< tdopen >}}
4
{{< tdclose >}}{{< tdopen >}}
Business of Biopharmaceuticals
{{< tdclose >}}{{< tdopen >}}

### Required

Silver, Steven. "Healthcare: Pharmaceuticals." *Standard & Poor's Industry Surveys*. August 13, 2009. *S&P Net Advantage*.

Lawrence, Stacy. "[Looking for an Oasis](http://www.biocentury.com/biotech-pharma-news/finance/2008-01-14/finance-2008-financial-markets-preview-looking-for-an-oasis-a)." *BioCentury, The Bernstein Report on Biobusiness* 16, no. 3 (2008): A1–A10.

Johnson, Avery. "[As Drug Industry Struggles, Chemists Face Layoff Wave](http://online.wsj.com/articles/SB119733600536720234)," *Wall Street Journal*, December 11, 2007.

Martinez, Barbara. "[Big Pharma Faces Grim Prognosis: Industry Fails to Find New Drugs to Replace Wonders Like Lipitor](http://online.wsj.com/articles/SB119689933952615133)," *Wall Street Journal*, December 6, 2007.

Silberman, Steve. "[Placebos are Getting More Effective. Drugmakers are Desperate to Know Why](http://archive.wired.com/medtech/drugs/magazine/17-09/ff_placebo_effect?currentPage=all)." *Wired Magazine* 17.09, August 2009.

### Recommended

[Merck & Schering-Plough Merger Investor Presentation (PDF)](http://media.corporate-ir.net/media_files/irol/89/89839/FINAL_Merck_Schering-Plough_Presentation.pdf) March 9, 2009. Merck Schering-Plough.

Schoeberl, B., E. A. Pace, et al. "[Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis](http://dx.doi.org/10.1126/scisignal.2000352)." *Science Signaling* 77, no. 2 (2009): ra31.

{{< tdclose >}}{{< trclose >}}{{< tropen >}}{{< tdopen >}}
5
{{< tdclose >}}{{< tdopen >}}
Accelerating Cancer Cures: A Global Frontier
{{< tdclose >}}{{< tdopen >}}
Skloot, Rebecca. "[*About The Immortal Life of Henrietta Lacks*](http://rebeccaskloot.com/the-immortal-life/)."
{{< tdclose >}}{{< trclose >}}{{< tropen >}}{{< tdopen >}}
6
{{< tdclose >}}{{< tdopen >}}
Clinical Drug Development
{{< tdclose >}}{{< tdopen >}}
Burton, Thomas M. "[By Learning from Failures, Lilly Keeps Drug Pipeline Full](http://online.wsj.com/articles/SB108249266648388235)," *Wall Street Journal*, April 21, 2004.
{{< tdclose >}}{{< trclose >}}{{< tropen >}}{{< tdopen >}}
7
{{< tdclose >}}{{< tdopen >}}
Drug Delivery Systems
{{< tdclose >}}{{< tdopen >}}

### Recommended

Alves, S., E. Régulier, et al. "[Striatal and Nigral Pathology in a Lentiviral Rat Model of Machado-Joseph Disease](http://dx.doi.org/10.1093/hmg/ddn106)." *Human Molecular Genetics* 17, no. 14 (2008): 2071–83.

Moreira, J. N., A. Santos, et al. "[Non-Viral Lipid-Based Nanoparticles for Targeted Cancer Systemic Gene Silencing](http://cnc.cj.uc.pt/msbiocel/private/LabRot/JNN08.pdf)." *Journal of Nanoscience and Nanotechnology* 8, no. 18 (2008): 2187–204.

{{< tdclose >}}{{< trclose >}}{{< tropen >}}{{< tdopen >}}
8–10
{{< tdclose >}}{{< tdopen >}}

Regulation

Emerging Pharmaceutical Science and Technology I

Manufacturing I

Reimbursement

Emerging Pharmaceutical Science and Technology II

{{< tdclose >}}{{< tdopen >}}

### Required

Rubin, L. "[Stem Cells and Drug Discovery: The Beginning of a New Era?](http://dx.doi.org/10.1016/j.cell.2008.02.010)" *Cell* 132 (2008): 549–52.

### Recommended

Radley, D. C., S. N. Finkelstein, et al. "[Off-label Prescribing Among Office-based Physicians](http://dx.doi.org/10.1001/archinte.166.9.1021)." *Archives of Internal Medicine* 166 no. 9 (2006): 1021–26.

Rubin, L., and F. J. de Sauvage. "[Targeting the Hedgehog Pathway in Cancer](http://dx.doi.org/10.1177/1758834010366430)." *Nature Reviews Drug Discovery* 5, no. 12 (2006): 1026–33.

[*The Burrill Report*](https://web.archive.org/web/20131002175503/http://www.burrillreport.com/article-the_september_2013_issue_of_the_burrill_report.html) 3, no. 9 (2013).

Jones, Matt. "GenomeWeb Feature: Slow, Steady Decline in NIH Funding Leads Researchers to Fear Future Cuts," *GenomeWeb Daily News*, July 18, 2013.

Philippidis, Alex. "[Researchers Chafe as NIH Budgets Shrivel](http://www.genengnews.com/insight-and-intelligenceand153/researchers-chafe-as-nih-budgets-shrivel/77899895/)," *Genetic Engineering & Biotechnology News*, September 13, 2013.

"[As VC Falters, Early-stage Biotechs Look Elsewhere for Cash](http://www.fiercebiotech.com/story/vc-falters-early-stage-biotechs-look-elsewhere-cash/2013-10-21)," *FierceBiotech*, October 21, 2013.

"Universities Stepping Up Efforts To Discover Drugs," *Forbes*, October 21, 2013.

{{< tdclose >}}{{< trclose >}}{{< tropen >}}{{< tdopen >}}
11–13
{{< tdclose >}}{{< tdopen >}}

Manufacturing II

Manufacturing III

Student Presentations

{{< tdclose >}}{{< tdopen >}}

### Required

Thayer, A. M. "[The New Copycats](http://cen.acs.org/articles/91/i40/New-Copycats.html)." *Chemical & Engineering News* 91, no. 40 (2013): 15–23.

Wechsler, J. "[Drug Quality at Center Stage for FDA and Manufacturers](http://www.biopharminternational.com/drug-quality-center-stage-fda-and-manufacturers)." *BioPharm International* 26, no. 1 (2013): 10–12.

Kozlowski, S., J. Woodcock, et al. "[Developing the Nation's Biosimilars Program](http://dx.doi.org/10.1056/NEJMp1107285)." *The New England Journal of Medicine* 365, no. 5 (2011): 385–88.

Thomas, Katie. "[Lapses at Big Drug Factories Add to Shortages and Danger](http://www.nytimes.com/2012/10/18/business/drug-makers-stalled-in-a-cycle-of-quality-lapses-and-shortages.html?pagewanted=all&_r=1&)," *New York Times*, October 17, 2012.

Basu, P., G. Joglekar, et al. "[Analysis of Manufacturing Costs in Pharmaceutical Companies](http://dx.doi.org/10.1007/s12247-008-9024-4)." *Journal of Pharmaceutical Innovation* 3, no. 1 (2008): 30–40.

["Quality Manufacturing: A Blockbuster Opportunity for Pharmaceuticals, An Economist Intelligence Unit White Paper Written in Co-operation with Oracle." (PDF)](http://graphics.eiu.com/files/ad_pdfs/eiu_oracle_pharma_wp.pdf) *Economist Intelligence Unit, The Economist*, September 2005.

"[Business: Trouble in the Making; Pharmaceuticals](http://www.economist.com/node/1302425)." *The Economist* 364, no. 8288 (2002).

### Recommended

["Guidance for Industry Q8(R2) Pharmaceutical Development." (PDF)](http://www.fda.gov/downloads/Drugs/Guidances/ucm073507.pdf) ICH Revision 2. U.S. Department of Health and Human Services, Food and Drug Administration, November 2009.

["Guidance for Industry Q10 Pharmaceutical Quality System." (PDF)](http://www.fda.gov/downloads/Drugs/Guidances/ucm073517.pdf) ICH. U.S. Department of Health and Human Services, Food and Drug Administration, April 2009.

{{< tdclose >}}{{< trclose >}}{{< tbodyclose >}}{{< tableclose >}}